{"cik":1318641,"taxonomy":"us-gaap","tag":"Goodwill","label":"Goodwill","description":"Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.","entityName":"Statera Biopharma, Inc.","units":{"USD":[{"end":"2020-12-30","val":0,"accn":"0001437749-21-026749","fy":2021,"fp":"Q3","form":"10-Q","filed":"2021-11-15"},{"end":"2020-12-31","val":0,"accn":"0001437749-22-023703","fy":2021,"fp":"FY","form":"10-K","filed":"2022-10-06","frame":"CY2020Q4I"},{"end":"2021-09-30","val":76972668,"accn":"0001437749-21-026749","fy":2021,"fp":"Q3","form":"10-Q","filed":"2021-11-15","frame":"CY2021Q3I"},{"end":"2021-12-31","val":9267007,"accn":"0001437749-22-023703","fy":2021,"fp":"FY","form":"10-K","filed":"2022-10-06"},{"end":"2021-12-31","val":9267007,"accn":"0001437749-22-024497","fy":2022,"fp":"Q1","form":"10-Q","filed":"2022-10-21"},{"end":"2021-12-31","val":9267007,"accn":"0001437749-22-025006","fy":2022,"fp":"Q2","form":"10-Q","filed":"2022-10-28"},{"end":"2021-12-31","val":9267007,"accn":"0001437749-22-027371","fy":2022,"fp":"Q3","form":"10-Q","filed":"2022-11-14","frame":"CY2021Q4I"},{"end":"2022-03-31","val":9267007,"accn":"0001437749-22-024497","fy":2022,"fp":"Q1","form":"10-Q","filed":"2022-10-21","frame":"CY2022Q1I"},{"end":"2022-06-30","val":9267007,"accn":"0001437749-22-025006","fy":2022,"fp":"Q2","form":"10-Q","filed":"2022-10-28","frame":"CY2022Q2I"},{"end":"2022-09-30","val":9267007,"accn":"0001437749-22-027371","fy":2022,"fp":"Q3","form":"10-Q","filed":"2022-11-14","frame":"CY2022Q3I"}]}}